Free Newsletter
Elan forecasts rare profit for 2010
Free newsletter via e-mail
Tools
Increased demand for its multiple sclerosis drug Tysabri and a tie-up with Johnson & Johnson helped trim losses at Elan, leading the Irish pharma to predict that in 2010, it would make an operating profit for the first time in nine years. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: